P021 vs Dihexa

Both are small experimental compounds for neurodegeneration research. P021 is derived from ciliary neurotrophic factor and promotes neurogenesis in mouse models; dihexa acts via HGF/c-Met.

HPLC tested · JanoshikJanoshik CertificatesNationwide DeliveryResearch Only

🧪

P021

A tetrapeptide derived from the most active region of ciliary neurotrophic factor (CNTF), studied for neurogenesis and synaptic plasticity.

BEST STUDIED FOR

Nootropic & neuro

Read the cited profile →

🧪

Dihexa

A small, blood–brain-barrier-permeable angiotensin IV analogue reported to act through the hepatocyte growth factor (HGF)/c-Met system.

BEST STUDIED FOR

Nootropic & neuro

Read the cited profile →

SIDE BY SIDE

	P021	Dihexa
The key difference	CNTF-derived peptidergic compound	Angiotensin IV-derived peptide
Class	Nootropic & neuro	Nootropic & neuro
Mechanism	Neurotrophic factors cannot cross the blood–brain barrier and have short half-lives.	Dihexa was developed from angiotensin IV-related peptides with pro-cognitive effects.
Status	Preclinical (ageing, Alzheimer’s, traumatic brain injury and CDKL5 models). No human studies.	Preclinical only (rodent cognitive and neurodegeneration models, hair-cell protection, nerve repair). No human trials published.
Reported safety signals	No human safety data.	No human safety data. Because HGF/c-Met is also an oncogenic pathway, long-term activation is a theoretical concern raised in the field.
A key study	An 11-mer CNTF-derived peptide enhanced neurogenesis, synaptic plasticity and memory in mice. (Neurobiol Aging 2011, PMID 19767127)	Reported that the pro-cognitive and synaptogenic effects of AngIV-derived peptides including dihexa depend on HGF/c-Met activation. (J Pharmacol Exp Ther 2014, PMID 25187433)

WHEN TO RESEARCH WHICH

Both are preclinical; the choice follows the pathway under study. Both are discussed here strictly as research compounds; nothing on this page is medical advice or a dosing guide.

REFERENCES (PUBMED)

[P021] Enhancement of dentate gyrus neurogenesis, dendritic and synaptic plasticity and memory by a neurotrophic peptide — Neurobiol Aging 2011. PMID 19767127
[P021] Prevention of dendritic and synaptic deficits and cognitive impairment with a neurotrophic compound — Alzheimers Res Ther 2017. PMID 28655344
[P021] Rescue of cognitive-aging by administration of a neurogenic and/or neurotrophic compound — Neurobiol Aging 2014. PMID 24702821
[Dihexa] The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-met system — J Pharmacol Exp Ther 2014. PMID 25187433
[Dihexa] AngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathway — Brain Sci 2021. PMID 34827486
[Dihexa] The development of small molecule angiotensin IV analogs to treat Alzheimer’s and Parkinson’s diseases — Prog Neurobiol 2015. PMID 25455861

FREQUENTLY ASKED

What is the difference between P021 and Dihexa?

Both are small experimental compounds for neurodegeneration research. P021 is derived from ciliary neurotrophic factor and promotes neurogenesis in mouse models; dihexa acts via HGF/c-Met.

What is the regulatory status of P021 and Dihexa?

P021: Preclinical (ageing, Alzheimer’s, traumatic brain injury and CDKL5 models). No human studies. Dihexa: Preclinical only (rodent cognitive and neurodegeneration models, hair-cell protection, nerve repair). No human trials published.

What safety signals have been reported?

P021: No human safety data. Dihexa: No human safety data. Because HGF/c-Met is also an oncogenic pathway, long-term activation is a theoretical concern raised in the field.

Which studies is this comparison based on?

For P021: “Enhancement of dentate gyrus neurogenesis, dendritic and synaptic plasticity and memory by a neurotrophic peptide” (PMID 19767127); “Prevention of dendritic and synaptic deficits and cognitive impairment with a neurotrophic compound” (PMID 28655344); “Rescue of cognitive-aging by administration of a neurogenic and/or neurotrophic compound” (PMID 24702821). For Dihexa: “The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-met system” (PMID 25187433); “AngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathway” (PMID 34827486); “The development of small molecule angiotensin IV analogs to treat Alzheimer’s and Parkinson’s diseases” (PMID 25455861).